Soaring obesity in US ­children is creating a dramatic increase in the number taking medicines for type-II diabetes and those with diabetes-related conditions, according to a Financial Times analysis of prescription data.

The analysis, for the FT by Medco, the largest US drug benefits manager, found the number of children taking medicine for Type-II diabetes more than doubled between 2001 and 2005.